 |
| Global BRAF Kinase Inhibitors Market Size |
The BRAF kinase inhibitors market is
primarily driven by the rising prevalence of cancers requiring targeted
therapies. BRAF kinase inhibitors help in targeting tumors with mutated BRAF
genes and are commonly used in cancers like melanoma, lung cancer, and
colorectal cancer. BRAF inhibitors block the RAF/MEK/ERK pathway and prevent
cell proliferation. They have significantly improved response rates and progression-free
survival in BRAF-mutated cancers.
The global BRAF kinase inhibitors market is estimated
to be valued at US$ 1364.56 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period
2024 to 2030.
Key Takeaways
Key players operating in the BRAF kinase inhibitors market are Hoffmann-La
Roche Ltd, Siemens Healthineers AG, Abbott Laboratories, Thermo Fisher
Scientific Inc., Danaher Corporation, Sysmex Corporation, Becton, Dickinson and
Company, Bio-Rad Laboratories, Inc., Quidel Corporation, Hologic, Inc., Ortho
Clinical Diagnostics, Beckman Coulter, Inc. (a subsidiary of Danaher
Corporation), BioMérieux SA, Trinity Biotech plc, EKF Diagnostics Holdings
plc.
The key opportunities in the Global
BRAF Kinase Inhibitors Market Size include the growing trend of biomarker-driven
drug development and approvals. Pharmaceutical companies are developing
targeted therapies for specific patient populations based on genetic mutations.
Moreover, emerging economies provide lucrative growth opportunities owing to improving
access to healthcare services and increasing uptake of novel anti-cancer drugs.
Major players are focused on the global expansion of their BRAF inhibitors
portfolio through large clinical trials evaluating new indications. For
instance, Roche received approval for Cotellic (cobimetinib) in combination
with Zelboraf (vemurafenib) in Europe for advanced BRAF V600 mutant non-small
cell lung cancer in 2018 based on superiority demonstrated in the phase III
cobra trial.
Market drivers include rising healthcare expenditure in developing nations
enabling greater access to premium drug therapies. Furthermore, the increasing
adoption of companion diagnostics for patient selection along with combination
therapies is boosting the efficacy of BRAF inhibitors and clinical outcomes.
However, the market faces restraints from the high pricing pressures and
stringent regulations around drug approvals. Additionally, drug resistance
develops quickly in cancer cells limiting the long-term efficacy of targeted
therapies. Managing drug resistance remains a key challenge and the focus of
ongoing research. Safety issues related to adverse effects can also negatively
impact market growth.
Segment Analysis
The Braf kinase inhibitor market is dominated by the Melanoma segment. Melanoma
holds the largest share of the global BRAF kinase inhibitors market as these
drugs are used as the standard treatment option for advanced and metastatic
melanoma patients with BRAF mutation. As per studies, around 50% of melanomas
have the BRAF mutation, making this cancer highly susceptible to treatment with
BRAF inhibitors. The melanoma segment is expected to continue dominating the
market over the forecast period owing to high prevalence of the disease and
increased adoption of targeted therapies for melanoma treatment.
The non-small cell lung cancer (NSCLC) segment is the second largest
sub-segment in the market. Though the percentage of patients with BRAF
mutations is lower for NSCLC as compared to melanoma, the high incidence rate
of NSCLC makes it one of the major application areas for BRAF inhibitors. BRAF
inhibitors in combination with other drugs are being studied for treatment of
NSCLC patients with BRAF mutations.
Global Analysis
North America currently dominates the global BRAF kinase inhibitors market and
is expected to continue its dominance over the forecast period. Factors such as
high adoption of premium-priced targeted therapies, strong presence of major
drug manufacturers, and well-developed healthcare infrastructure drive the
North American market. Within the region, the US represents the largest market
owing to new product approvals and launches, large cancer patient population,
and high healthcare expenditure.
Europe is the second largest regional market and is expected to exhibit high
growth over the forecast period owing to growing cancer research as well as
increasing awareness about targeted therapies. Rising investments by public and
private players to develop advanced treatments also support the European market
growth. Asia Pacific is anticipated to be the fastest growing regional market
during the forecast period. Factors such as improving healthcare
infrastructure, increasing research initiatives, rising prevalence of cancer,
and growing access to advanced therapies drive the APAC market.
Get More Insights On This Topic: BRAF
Kinase Inhibitors Market